164 related articles for article (PubMed ID: 25519826)
1. An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Sai Chandran BV; Balachander J; Adithan C
Eur J Clin Pharmacol; 2015 Feb; 71(2):173-81. PubMed ID: 25519826
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients.
Elkhazraji A; Bouaiti EA; Boulahyaoui H; Nahmtchougli CP; Zahid H; Bensaid M; Ibrahimi A; Messaoudi N
Drug Discov Ther; 2018; 12(2):68-76. PubMed ID: 29760340
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.
Krishna Kumar D; Madhan S; Balachander J; Sai Chandran BV; Thamijarassy B; Adithan C
Thromb Res; 2013 Apr; 131(4):363-7. PubMed ID: 23473641
[TBL] [Abstract][Full Text] [Related]
5. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.
Pérez-Andreu V; Roldán V; López-Fernández MF; Antón AI; Alberca I; Corral J; Montes R; García-Barberá N; Ferrando F; Vicente V; González-Conejero R
J Thromb Haemost; 2010 May; 8(5):1012-7. PubMed ID: 20149073
[TBL] [Abstract][Full Text] [Related]
7. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
[TBL] [Abstract][Full Text] [Related]
8. CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant.
Rathore SS; Agarwal SK; Pande S; Singh SK; Mittal T; Mittal B
Indian J Med Res; 2014 Apr; 139(4):572-8. PubMed ID: 24927344
[TBL] [Abstract][Full Text] [Related]
9. Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.
Smires FZ; Moreau C; Habbal R; Siguret V; Fadili S; Golmard JL; Assaidi A; Beaune P; Loriot MA; Nadifi S
J Clin Pharm Ther; 2012 Oct; 37(5):594-8. PubMed ID: 22486182
[TBL] [Abstract][Full Text] [Related]
10. Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.
Ragia G; Karantza IM; Kelli-Kota E; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
Drug Metab Pers Ther; 2017 Dec; 32(4):183-190. PubMed ID: 29252193
[TBL] [Abstract][Full Text] [Related]
11. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
Cerezo-Manchado JJ; Roldan V; Rosafalco M; Anton AI; Arroyo AB; Garcia-Barbera N; Martínez AB; Padilla J; Corral J; Vicente V; Gonzalez-Conejero R
Pharmacogenomics; 2014 May; 15(7):987-96. PubMed ID: 24956252
[TBL] [Abstract][Full Text] [Related]
12. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639GKaur A; Khan F; Agrawal SS; Kapoor A; Agarwal SK; Phadke SR
Indian J Med Res; 2013 Jan; 137(1):203-9. PubMed ID: 23481074
[TBL] [Abstract][Full Text] [Related]
14. Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.
Kalpana SR; Bharath G; Manjunath CN; Christopher R
Clin Appl Thromb Hemost; 2017 Oct; 23(7):876-882. PubMed ID: 27335128
[TBL] [Abstract][Full Text] [Related]
15. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
16. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.
Varnai R; Sipeky C; Nagy L; Balogh S; Melegh B
Environ Toxicol Pharmacol; 2017 Dec; 56():282-289. PubMed ID: 29055218
[TBL] [Abstract][Full Text] [Related]
18. Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.
Fohner AE; Robinson R; Yracheta J; Dillard DA; Schilling B; Khan B; Hopkins S; Boyer B; Black J; Wiener H; Tiwari HK; Gordon A; Nickerson D; Tsai JM; Farin FM; Thornton TA; Rettie AE; Thummel KE
Pharmacogenet Genomics; 2015 Jul; 25(7):343-353. PubMed ID: 25946405
[TBL] [Abstract][Full Text] [Related]
19. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
20. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
